Distinct from the results of pan-cancer analysis of NAT10, our proposition demonstrates the difference between NAT10 and THUMPD1 in clinical and immunological function, though they both serve as the writing tools of ac4C [34]. This evidence concerns the gene NAT10 and cancer.